News archive

Protein loss in urine predicts effectiveness of hypertension medication

Date:February 06, 2008

People with albuminuria, increased protein loss in the urine, have an increased risk of kidney and cardiovascular diseases. Cornelis Boersma, pharmacist and PhD student at the University of Groningen, has analysed the medical data of over 8,500 Groningers and discovered that preventive measures work better if the amount of protein loss is higher. This has important consequences for future prevention programmes. The results of this research were published on 30 January 2008 in the British Journal of Clinical Pharmacology.

The kidneys filter urea from the blood. This occurs in the millions of capillaries (very thin blood vessels) which make up a kidney. If the filtering does not work properly, protein is released into the urine – an indication that the capillaries are not functioning properly. At the same time, this can be a sign that the rest of the blood vessels in the body are not functioning properly either.

PREVEND study

The PREVEND study was set up in order to investigate whether people with protein loss in the urine have an increased risk of kidney and cardiovascular diseases  (PREVEND = Prevention of REnal and Vascular ENd-stage Disease). To this end, over 8,500 Groningers submitted urine in 1997 and the protein levels in these samples were carefully measured in the laboratory. The Groningers were then tracked for years, particularly concerning their medicine use and the occurrence of cardiovascular disease.

ACE inhibitor

A recent analysis of the Groningen data by Cornelis Boersma has revealed that people with high blood pressure only have an increased risk of cardiovascular disease if they also have protein loss in the urine. What is more important is the discovery that the effectiveness of antihypertensives depends on the level of protein loss in the urine:  the greater the protein loss, the more effective the hypertension medications are against cardiovascular disease. A GP has to treat 111 people with hypertension in order to prevent 1 instance of stroke or heart attack if there is no protein loss, but only 8 if there is protein loss. In addition, these new data suggest that – if you want to prevent cardiovascular disease – the best medication for people with more protein loss is perhaps a so-called ACE inhibitor (a specific antihypertensive).

Screening

These results will have important consequences for any large-scale prevention programme: by screening for albuminuria, people with hypertension, and thus a greater risk of cardiovascular disease, can be more quickly identified. In addition, it is now possible to determine which people can best be prescribed antihypertensives. In such a prevention programme, for example, people's urine could be tested in a laboratory once every four years and when anomalous values are discovered medication can be prescribed. The researchers now want to investigate which would be the most beneficial and cost-effective screening programme for which groups of people.

Authors’ CVs

Cornelis Boersma (1978) graduated in Pharmacy in 2003 at the University of Groningen, specializing in Pharmacoeconomics. He is currently a PhD student in the Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy department. His research concentrates mainly on the cost effectiveness of screening on the prevention of kidney and cardiovascular diseases. Boersma is the main author of the article in the British Journal of Clinical Pharmacology.

Ron Gansevoort (1964) graduated in Medicine from the University of Groningen in 1989. In 1995 he gained his PhD with honours from the same university. His thesis is entitled ‘Mechanism and benefits of the antiproteinuric effect of ACE-inhibition’. Since 2002 he has been internist-nephrologist at the University Medical Center Groningen and since 2003 the coordinator of the PREVEND study. He is a member of the Wetenschappelijke Adviescommissie Preventie [Academic Advisory Committee for Prevention] of the Nederlandse Hartstichting [Dutch Heart Foundation]. He is co-author of the article in the British Journal of Clinical Pharmacology.

Note for the press

For more information: Dr R. Gansevoort, tel. 050-363 2955, e-mail: r.t.gansevoort@int.umcg.nl

Link to the article:
http://www.prevend.org/Userfiles/109Boersma.pdf

Last modified:September 04, 2012 14:13
Also available in: